{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:30:01Z","timestamp":1791041401944,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"DOI":"10.7759\/cureus.88780","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T04:51:06Z","timestamp":1753505466000},"source":"Crossref","is-referenced-by-count":1,"title":["Endoscopic and Histopathologic Findings of Rituximab-Associated Colitis in a Patient With Scleroderma"],"prefix":"10.7759","author":[{"given":"Roberto A","family":"Alvarado-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M","family":"Reyes-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoeli M","family":"Escandon-Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia D","family":"Lopez Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M","family":"Ayuso-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Moreno-Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13 Suppl 2","author":"Cerny T","year":"2002","unstructured":"Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002, 13 Suppl 2:S3-10. 10.1097\/00001813-200211002-00002","journal-title":"Anticancer Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith MR","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003, 22:7359-68. 10.1038\/sj.onc.1206939","journal-title":"Oncogene"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac J","year":"2018","unstructured":"MacIsaac J, Siddiqui R, Jamula E, et al.. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion. 2018, 58:2729-35. 10.1111\/trf.14841","journal-title":"Transfusion"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111051","article-title":"B cell-mediated regulatory mechanisms control tumor-promoting intestinal inflammation","volume":"40","author":"Melcher C","year":"2022","unstructured":"Melcher C, Yu J, Duong VH, et al.. B cell-mediated regulatory mechanisms control tumor-promoting intestinal inflammation. Cell Rep. 2022, 40:111051. 10.1016\/j.celrep.2022.111051","journal-title":"Cell Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.03.027","article-title":"De novo colitis associated with rituximab in 21 patients at a tertiary center","volume":"18","author":"Eckmann JD","year":"2020","unstructured":"Eckmann JD, Chedid V, Quinn KP, Bonthu N, Nehra V, Raffals LE. De novo colitis associated with rituximab in 21 patients at a tertiary center. Clin Gastroenterol Hepatol. 2020, 18:252-3. 10.1016\/j.cgh.2019.03.027","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13577","article-title":"Efficient long-term depletion of CD20(+) B cells by rituximab does not affect gut-resident plasma cells","volume":"1415","author":"Uzzan M","year":"2018","unstructured":"Uzzan M, Ko HM, Rosenstein AK, Pourmand K, Colombel JF, Mehandru S. Efficient long-term depletion of CD20(+) B cells by rituximab does not affect gut-resident plasma cells. Ann N Y Acad Sci. 2018, 1415:5-10. 10.1111\/nyas.13577","journal-title":"Ann N Y Acad Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38207","article-title":"Rituximab-induced colitis and esophagitis in a patient with granulomatosis with polyangiitis","volume":"15","author":"Boateng WK","year":"2023","unstructured":"Boateng WK, Nkeangu FJ, Castillo MH, Marian V, Shen T. Rituximab-induced colitis and esophagitis in a patient with granulomatosis with polyangiitis. Cureus. 2023, 15:e38207. 10.7759\/cureus.38207","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1186016","article-title":"Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review","volume":"14","author":"Quesada-Sim\u00f3 A","year":"2023","unstructured":"Quesada-Sim\u00f3 A, Garrido-Mar\u00edn A, Nos P, Gil-Perot\u00edn S. Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review. Front Pharmacol. 2023, 14:1186016. 10.3389\/fphar.2023.1186016","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.016","article-title":"Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation","volume":"41","author":"Matsumoto M","year":"2014","unstructured":"Matsumoto M, Baba A, Yokota T, et al.. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity. 2014, 41:1040-51. 10.1016\/j.immuni.2014.10.016","journal-title":"Immunity"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri C","year":"2012","unstructured":"Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012, 30:221-41. 10.1146\/annurev-immunol-020711-074934","journal-title":"Annu Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.06.001","article-title":"European consensus on the histopathology of inflammatory bowel disease","volume":"7","author":"Magro F","year":"2013","unstructured":"Magro F, Langner C, Driessen A, et al.. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013, 7:827-51. 10.1016\/j.crohns.2013.06.001","journal-title":"J Crohns Colitis"},{"key":"ref12","article-title":"Faecal Calprotectin Diagnostic Tests for Inflammatory Diseases of the Bowel","year":"2013","unstructured":"Faecal Calprotectin Diagnostic Tests for Inflammatory Diseases of the Bowel. National Institute for Health and Care Excellence (NICE), London; 2013."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384853-endoscopic-and-histopathologic-findings-of-rituximab-associated-colitis-in-a-patient-with-scleroderma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T04:51:07Z","timestamp":1753505467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384853-endoscopic-and-histopathologic-findings-of-rituximab-associated-colitis-in-a-patient-with-scleroderma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.88780","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}